Biomarkers: Found in translation;Les biomarqueurs: Found in translation

Medecine/Sciences

Volumn 25, Issue 4, 2009, Pages 423-430

  Lockhart, Brian P ^a   Walther, Bernard ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

BIOLOGICAL MARKER; NEW DRUG;

DISEASE COURSE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG MONITORING; ECONOMICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DRUG MONITORING; DRUGS, INVESTIGATIONAL; HUMANS; PROGNOSIS;

EID: 70349237588     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2009254423     Document Type: Review

References (16)

1. Schmid F, Smith DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005 ; 10 : 1031-1039. (Pubitemid 41074141)
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 ; 3 : 711-714.
3. Kola I, Hazuda D. Innovation and greater probability of success in drug discovery and development: from target to biomarkers. Curr Opin Biotechnol 2005 ; 16 : 644-646. (Pubitemid 41654643)
4. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today 2006 ; 11 : 355-363.
5. Graeber TG, Sawyers CL. Cross-species comparisons of cancer signaling. Nat Genet 2005 ; 37 : 7-8. (Pubitemid 40070929)
6. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 2005 ; 4 : 161-165. (Pubitemid 40277495)
7. Littman BH, Williams SA. The ultimate model organism: progress in experimental medicine. Nat Rev Drug Discov 2005 ; 4 : 631-638. (Pubitemid 41149756)
8. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006 ; 5 : 741-754. (Pubitemid 44323701)
9. Chen H, Churfat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996 ; 84 : 491-495. (Pubitemid 26060722)
10. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000 ; 405 : 857-865. (Pubitemid 30407864)
11. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003 ; 19(11) : 660-666. (Pubitemid 37338386)
12. Pasanen MK. SLC01B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006 ; 16 : 873-879. (Pubitemid 44772805)
13. Wang Y, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009 ; 106 : 226-231.
14. Caldwell MD. CYP4F2 genetic variant alters required warfarin dose. Blood 2008 ; 111 : 4106-4112.
15. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003 ; 2 : 566-580. (Pubitemid 37361748)
16. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007 ; 6 : 287-293. (Pubitemid 46505879)